CENTESSA PHARMACEUTICALS PLC (CNTA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$40.500.00%
Close 2026-06-25 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CNTA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers · Company calendar date is not available
CNTA — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-06-24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. In connection with the completion of the Acquisition, Centessa requested that The Nasdaq Stock Market LLC (“ Nasdaq ”) (a) halt trading of the Company ADSs effective as of 8:00 p.m. New York City time on June 23, 2026 and (b) file with the Securities and Exchange Commission (the “ SEC ”) a Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange A…
Why it matters: Changes in leadership can affect company plans. This can change how investors feel.
Supportive ifNo more executives left after the CEO change in early 2026.
Worry ifMore senior executives leave after the CEO change.
Why it matters: Centessa had negative operating cash flow and net income in 2026-Q1. A shorter runway would raise concern about funding needs.
Worry ifA company filing says its cash will not fund operations through mid-2027.
Less concerning ifA company filing confirms cash still funds operations into mid-2027 or later.
Why it matters: If healthcare sector revenue growth speeds up, it may help Centessa. This could make investors feel better.
Supportive ifHealthcare sector revenue growth speeds up again, going above 10%.
Worry ifHealthcare sector revenue growth keeps slowing down, staying below 10%.
Why it matters: His leadership direction will shape the company's future. Clear strategy can boost investor confidence.
Supportive ifAccardi shares a clear plan in a public statement or interview.
Worry ifAccardi does not give a clear strategy or vision for the company.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$25 on $10,000 · ±0.3% | How much price usually moves either way. |
| Bad day | $361 loss on $10,000 · 3.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,638 loss on $10,000 · 26.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The new CEO's leadership style may affect company strategy and performance. Investors will look for signs of stability.
Watch forEmployees or stakeholders may give positive feedback about the new CEO's plans next quarter.
Also watch forWatch for news about more executive departures. There may also be leadership problems in the next quarter.
Why it matters: The acquisition by Eli Lilly is a key growth milestone. It will impact Centessa's future direction and resources.
Supportive ifEli Lilly will make an official announcement. This will confirm their resource integration by the end of Q4 2026.
Worry ifDelays or issues reported in the integration process beyond Q4 2026.
Why it matters: Good integration helps operations run smoothly. It also builds trust with investors.
Supportive ifA press release will announce key successes in the Eli Lilly integration.
Worry ifNo updates or bad news on the integration with Eli Lilly.
Why it matters: The CEO change and senior exits followed the deal. A clear leadership plan can show who will guide the acquired programs.
Watch forLilly names leaders for the acquired programs and confirms key work continues.
Also watch forLilly reports more leaders leaving because of the deal or pauses key work.
Why it matters: Managing cash burn is crucial for funding operations through mid-2027. Investors will want to see if the company can control its losses.
Worry ifOperating cash flow improves to less than negative $60M in the next quarter.
Less concerning ifOperating cash flow remains worse than negative $80M in the next quarter.
Why it matters: The CEO transition may affect the company's direction and execution of its plans. This could influence investor confidence.
Watch forDr. Accardi announces a new strategic plan that aligns with the acquisition.
Also watch forMore executives are leaving. This causes a lack of clear direction.
Why it matters: The acquisition closed on June 24, 2026. Lilly’s update can show how it plans to advance the acquired programs.
Watch forLilly names a Centessa program and states the next step or timing.
Also watch forLilly reports a program pause, stop, or delay beyond its stated timeline.